| 学科主题 | 临床医学 |
| Continued Overall Survival Benefit After 5 Years′ Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial | |
| San Miguel, Jesus F.1; Schlag, Rudolf2; Khuageva, Nuriet K.3; Dimopoulos, Meletios Athanasios4; Shpilberg, Ofer5; Kropff, Martin6; Spicka, Ivan7; Petrucci, Maria T.8; Palumbo, Antonio9; Samoilova, Olga S.10; Dmoszynska, Anna11; Abdulkadyrov, Kudrat M.12; Delforge, Michel13; Jiang, Bin14; Mateos, Maria-Victoria1; Anderson, Kenneth C.; Esseltine, Dixie-Lee16; Liu, Kevin17; Deraedt, William M.18; Cakana, Andrew Z.19; van de Velde, Helgi18; Richardson, Paul G.15 | |
| 刊名 | BLOOD
 |
| 2011-11-18 | |
| 卷 | 118期:21页:221-222 |
| 收录类别 | SCI ; ISTP |
| 文章类型 | Meeting Abstract |
| WOS标题词 | Science & Technology |
| 类目[WOS] | Hematology |
| 研究领域[WOS] | Hematology |
| 语种 | 英语 |
| WOS记录号 | WOS:000299597100477 |
| Citation statistics | |
| 文献类型 | 期刊论文 |
| 条目标识符 | http://ir.bjmu.edu.cn/handle/400002259/56547 |
| Collection | 北京大学第二临床医学院_血液科 |
| 作者单位 | 1.Janssen Res & Dev, High Wycombe, Bucks, England 2.Praxisklin Dr Schlag, Wurzburg, Germany 3.SP Botkin Moscow City Clin Hosp, Moscow, Russia 4.Rabin Med Ctr, Inst Hematol, Petah Tiqwa, Israel 5.Univ Munster, Munster, Germany 6.Charles Univ Prague, Prague, Czech Republic 7.Univ Roma La Sapienza, Rome, Italy 8.Belgian Hematol Soc, Myeloma Study Grp, Brussels, Belgium 9.Janssen Res & Dev, Raritan, NJ USA 10.Janssen Res & Dev, Beerse, Belgium 11.Nizhnii Novgorod Reg Clin Hosp, Novgorod, Russia 12.Med Univ Lublin, Lublin, Poland 13.St Petersburg Clin Res Inst Hematol & Transfusiol, St Petersburg, Russia 14.Hosp Clin Univ, Salamanca, Spain 15.Univ Athens, Sch Med, Dept Clin Therapeut, GR-11527 Athens, Greece 16.Univ Turin, Div Hematol, Myeloma Unit, AOU S Giovanni Battista, Turin, Italy 17.Peking Univ, Peoples Hosp, Inst Hematol, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Beijing 100871, Peoples R China 18.Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA 19.Millennium Pharmaceut Inc, Cambridge, MA USA |
| Recommended Citation GB/T 7714 | San Miguel, Jesus F.,Schlag, Rudolf,Khuageva, Nuriet K.,et al. Continued Overall Survival Benefit After 5 Years′ Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial[J]. BLOOD,2011,118(21):221-222. |
| APA | San Miguel, Jesus F..,Schlag, Rudolf.,Khuageva, Nuriet K..,Dimopoulos, Meletios Athanasios.,Shpilberg, Ofer.,...&Richardson, Paul G..(2011).Continued Overall Survival Benefit After 5 Years′ Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial.BLOOD,118(21),221-222. |
| MLA | San Miguel, Jesus F.,et al."Continued Overall Survival Benefit After 5 Years′ Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial".BLOOD 118.21(2011):221-222. |
| Files in This Item: | There are no files associated with this item. | |||||
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment